Reports FY23 revenue $18.141M, consensus $20.79M. “I anticipate that 2024 will be a productive year for Arbutus as we continue to advance the development of our HBV assets: imdusiran, our RNAi therapeutic, and AB-101, our oral checkpoint inhibitor,” said Michael J. McElhaugh, Interim President and Chief Executive Officer of Arbutus Biopharma. “To date, we have dosed more than 170 HBV patients with imdusiran and continue to see notable and sustained reductions in surface antigen. We believe that a combination therapy that reduces surface antigen, suppresses HBV DNA and boosts the host immune response will be necessary to functionally cure HBV. We are currently evaluating imdusiran with other immune modulators and expect multiple data readouts this year, including the potential to see undetectable surface antigen at end of treatment. These trials, in addition to our plans to initiate an imdusiran + durvalumab clinical trial, will help inform our later stage clinical development program in addition to the dose and dosing duration for AB-101, potentially expediting imdusiran + AB-101 combinations.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ABUS:
- Arbutus Biopharma (ABUS) Q4 Earnings Cheat Sheet
- Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
- Biotech Alert: Searches spiking for these stocks today
- Jefferies ‘encouraged thus far’ by Arbutus patent hearing
- Arbutus Biopharma lays out 2024 objectives, sees cash runway into Q1 of 2026